6 October 2020 - Oncternal Therapeutics today announced that the U.S. FDA has granted rare paediatric disease designation for TK216, an investigational potentially first-in-class targeted small-molecule inhibitor of the E26 transformation-specific family of oncoproteins, for treatment of Ewing sarcoma.

Ewing sarcoma is the second most common bone tumour among children and adolescents.

Read Oncternal Therapeutics press release